Following on from information provided to NICE by the company in September 2018, the appraisal of Abemaciclib monotherapy for treating advanced hormone-receptor positive, HER2-negative breast cancer after endocrine therapy and chemotherapy [ID1347] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1347 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 November 2022 | Discontinued. Following on from information provided to NICE by the company in September 2018, the appraisal of Abemaciclib monotherapy for treating advanced hormone-receptor positive, HER2-negative breast cancer after endocrine therapy and chemotherapy [ID1347] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 03 September 2018 | Suspended. Following on from advice received from the company, NICE has decided to suspend this appraisal from its work programme. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 03 September 2018 | As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of abemaciclib monotherapy for treating advanced hormone-receptor positive, HER2-negative breast cancer after endocrine therapy and chemotherapy. However, following on from advice received from the company, NICE has decided to suspend this appraisal from its work programme. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 19 October 2017 - 16 November 2017 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 01 October 2017 | In progress. Topic referred |
For further information on our processes and methods, please see our CHTE processes and methods manual